Novel CD40 : CD154 binding interruptor compounds and use thereof to treat immunological complications
申请人:——
公开号:US20040067982A1
公开(公告)日:2004-04-08
The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
本发明涉及新型CD40:CD154结合中断化合物以及使用这些化合物和包含它们的药物组合物,用于治疗与受试者中不适当的CD154激活相关的疾病。具体而言,本发明提供通过筛选小分子库以识别能够特异性结合CD154并中断CD40:CD154相互作用的化合物。